Table 6. Pharmacokinetics of DB829 Pharmacokinetics of DB829 in vervet monkeys with second stage HAT after the 10^th oral dose of DB868.

	Monkey	Tmax (day)	Cmax (nmol/L)	AUC0–63 (nmol/L•day)	t½ (day)
20 mg/kg × 10 days	573F	1	460	7700	48
	679F	0.33	630	13000	NC ‡
	689M	0.17	500	4700	180
	696M	0.17	530	5900	NC ‡
10 mg/kg × 10 days	688M	0.04	410	2500	NC ‡
	690F	2.0	340	5100	120
	695M	NC*	NC*	NC*	NC*
	697F	0.33	210	NC †	NC †
3 mg/kg × 10 days	670F	0.33	60	NC †	NC †
	687M	0.33	110	1800	NC ‡

T_max, time to reach C_max; C_max, maximum concentration; AUC_0–63, AUC from 0 to 63 days; t_½, terminal half-life; F, female; M, male; NC, not calculable;

* = data was too sparse to determine the T_max, C_max, AUC_0–63, and t_½ with confidence;

^† = data was too sparse to determine the AUC_0–63, and t_½ with confidence;

^‡ = data was insufficient in the terminal phase to determine the t_½ with confidence.